Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand
He, Wen-Qiang, Karl, Stephan, White, Michael T., Nguitragool, Wang, Monteiro, Wuelton, Kuehn, Andrea, Gruszczyk, Jakub, Franca, Camila T., Sattabongkot, Jetsumon, Lacerda, Marcus V.G., Thama, Wai-Hong, and Mueller, Ivo (2019) Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand. PLoS Neglected Tropical Diseases, 13 (8). e0007596.
|
PDF (Published Version)
- Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Background: The Plasmodium vivax Reticulocyte Binding Protein (PvRBP) family is involved in red blood cell recognition and members of this family are potential targets for antibodies that may block P. vivax invasion. To date, the acquisition of immunity against PvRBPs in low malaria transmission settings and in a broad age group of exposed individuals has not been investigated.
Methodology/principal findings: Total IgG antibody levels to six members of the PvRBP family (PvRBP1a, PvRBP1b, PvRBP2a, PvRBP2b, a non-binding fragment of PvRBP2c (PvRBP2cNB) and PvRBP2-P2) were measured in samples collected from individuals living in two regions of low P. vivax endemicity in Brazil and Thailand. In both settings, levels of total IgG to PvRBP1a, PvRBP2b, PvRBP2cNB, and PvRBP2P-2 increased significantly with age (rho = 0.17-0.49; P<0.001). IgG responses to PvRBP1a, PvRBP2b and PvRBP2cNB were significantly higher in infected individuals by using Wilcoxon's signed-rank test (P<0.001). Of the six PvRBPs examined, only antibodies to PvRBP2b were associated with protection against clinical malaria in both settings.
Conclusion/significance: Our results indicate that PvRBP2b warrants further preclinical development as a blood-stage vaccine candidate against P. vivax. Total IgG responses to PvRBPs were also shown to be promising immunological markers of exposure to P. vivax infection.
| Item ID: | 70960 |
|---|---|
| Item Type: | Article (Research - C1) |
| ISSN: | 1935-2735 |
| Copyright Information: | © 2019 He et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Funders: | National Health and Medical Research Council of Australia (NHMRC) |
| Projects and Grants: | NHMRC GNT1141441 |
| Date Deposited: | 24 Nov 2021 05:25 |
| FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3204 Immunology > 320402 Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) @ 100% |
| SEO Codes: | 20 HEALTH > 2004 Public health (excl. specific population health) > 200404 Disease distribution and transmission (incl. surveillance and response) @ 100% |
| Downloads: |
Total: 628 Last 12 Months: 99 |
| More Statistics |
Actions (Repository Staff Only)
 |
Item Control Page |